Lung cancer with acquired T790M resistance: erlotinib switched to afatinib while AZD9291/TAGRISSO trial was considered

Patient Info: Anonymized, Male | Stage Metastatic/Advanced

Biomarkers: Acquired resistance detected; other resistance findings also mentioned

As of January 2016, he had reached 2 years of survival but had confirmed acquired resistance including T790M, worsening symptoms, and a treatment change from erlotinib to afatinib while a TAGRISSO/AZD9291 trial was being considered.

Lung cancer progression on Tarceva with urgent T790M resistance testing planned

Patient Info: Anonymized, Male | Stage Metastatic/Advanced

Biomarkers: resistance suspected; bronchoscopy planned to test for it

As of January 2016, CT showed clear progression while he was taking Tarceva/erlotinib, so urgent bronchoscopy was planned to look for T790M resistance and guide the next treatment option.

EGFR-mutated NSCLC on Tarceva with CT follow-up pending and future resistance options discussed

Patient Info: Anonymized, Male

Biomarkers: EGFR mutation; T790M resistance discussed as a possible future resistance mechanism

As of December 2015, he was on Tarceva/erlotinib for EGFR-mutated NSCLC, had new cough/chest pain/fatigue, and was waiting for a control CT to clarify whether the tumor remained controlled.

Lung cancer on Tarceva with stable symptoms during summer follow-up

Patient Info: Anonymized, Male

As of July 2015, he was continuing Tarceva, felt strong overall, had no major cancer symptoms, and was waiting until October for the next CT while assuming the tumor remained stable.

Lung cancer on erlotinib with side effects and CT results pending

Patient Info: Anonymized, Male

As of March 2015, he was continuing erlotinib/Tarceva, dealing with side effects and anxiety while waiting for CT results, and receiving support from readers and other patients.

EGFR-mutated NSCLC on Erlotinib/Tarceva with March CT pending

Patient Info: Anonymized, Male

Biomarkers: EGFR mutation; T790M discussed as a possible later resistance mutation

As of February 2015, he was about 1.5 months into Erlotinib/Tarceva for EGFR-mutated NSCLC and was waiting for a March CT to know whether the tumor was controlled.

Lung cancer on Erlotinib/Tarceva with rash, dyspepsia, mouth irritation, and fatigue

Patient Info: Anonymized, Male

As of January 2015, he had been taking Erlotinib/Tarceva for more than 15 days, was managing early side effects, and was waiting for the March CT to show whether tumor growth had stabilized and whether there was metastasis.

Lung cancer diary: starting Tarceva and treatment-cost concerns

Patient Info: Anonymized

As of January 2015, the patient had just started Erlotinib/Tarceva for lung cancer, with early mild side effects and ongoing uncertainty about response.

Stage IIIA NSCLC with superior vena cava tumor thrombus: complete response to radiation and erlotinib

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR protein expression positive; EGFR gene mutation not tested because tumor sample was inadequate

Radiation plus erlotinib led to complete response of the primary lung tumor at 6 months, disappearance of the SVC thrombosis at 9 months, and no progression during 45 months of close follow-up on maintenance erlotinib.

PubMed CentralRead more →

Stage IV lung adenocarcinoma: partial responses to cisplatin-docetaxel and erlotinib, complicated by fistula

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Tumor genomic biomarkers not reported. EGFR testing result not reported; erlotinib was used as second-line therapy.

Metastatic Site: contralateral lung, pleura

Metastatic lung adenocarcinoma had partial response to chemotherapy and persistent partial response on erlotinib; after erlotinib was stopped for enterocutaneous fistula, she was alive and well without evidence of lung-cancer progression.

PubMed CentralRead more →